INOVIO to Present at Upcoming Scientific Conference
INOVIO (NASDAQ:INO), a biotechnology company specializing in DNA medicines, has announced its participation in the upcoming Orphan Drug Summit in Boston, Massachusetts. The company will present on July 16 at 4:30 PM ET, focusing on their DMAb Technology and its transformational potential in rare disease treatment.
The presentation will explore the capabilities of next generation DNA medicine technology in addressing rare diseases, as part of a conference that brings together industry leaders and innovators to discuss technological and manufacturing advancements in the rare disease space.
INOVIO (NASDAQ:INO), un'azienda biotecnologica specializzata in medicinali a base di DNA, ha annunciato la sua partecipazione al prossimo Orphan Drug Summit che si terrà a Boston, Massachusetts. L'azienda presenterà il 16 luglio alle 16:30 ET, concentrandosi sulla loro tecnologia DMAb e sul suo potenziale rivoluzionario nel trattamento delle malattie rare.
La presentazione esplorerà le capacità della tecnologia di medicina a base di DNA di nuova generazione nel trattamento delle malattie rare, nell'ambito di una conferenza che riunisce leader del settore e innovatori per discutere i progressi tecnologici e produttivi nel campo delle malattie rare.
INOVIO (NASDAQ:INO), una empresa biotecnológica especializada en medicamentos de ADN, ha anunciado su participación en la próxima Orphan Drug Summit en Boston, Massachusetts. La compañía presentará el 16 de julio a las 4:30 PM ET, enfocándose en su tecnología DMAb y su potencial transformador en el tratamiento de enfermedades raras.
La presentación explorará las capacidades de la tecnología de medicina de ADN de próxima generación para abordar enfermedades raras, como parte de una conferencia que reúne a líderes e innovadores de la industria para discutir avances tecnológicos y de fabricación en el ámbito de las enfermedades raras.
INOVIO (NASDAQ:INO)는 DNA 의약품을 전문으로 하는 생명공학 회사로, 매사추세츠주 보스턴에서 열리는 Orphan Drug Summit에 참여할 예정임을 발표했습니다. 회사는 7월 16일 오후 4시 30분(동부시간)에 DMAb 기술과 희귀질환 치료에 있어 그 변혁적 잠재력에 대해 발표할 예정입니다.
이번 발표에서는 차세대 DNA 의약 기술이 희귀질환 치료에 어떻게 기여할 수 있는지를 탐구할 예정이며, 이 컨퍼런스는 희귀질환 분야의 기술 및 제조 혁신을 논의하기 위해 업계 리더와 혁신가들이 모이는 자리입니다.
INOVIO (NASDAQ:INO), une entreprise de biotechnologie spécialisée dans les médicaments à base d'ADN, a annoncé sa participation au prochain Orphan Drug Summit à Boston, Massachusetts. La société présentera le 16 juillet à 16h30 ET, en mettant l'accent sur leur technologie DMAb et son potentiel transformateur dans le traitement des maladies rares.
La présentation explorera les capacités de la technologie de médecine à base d'ADN de nouvelle génération pour traiter les maladies rares, dans le cadre d'une conférence réunissant des leaders et des innovateurs de l'industrie pour discuter des avancées technologiques et de fabrication dans le domaine des maladies rares.
INOVIO (NASDAQ:INO), ein Biotechnologieunternehmen, das sich auf DNA-Medikamente spezialisiert hat, hat seine Teilnahme am bevorstehenden Orphan Drug Summit in Boston, Massachusetts, angekündigt. Das Unternehmen wird am 16. Juli um 16:30 Uhr ET präsentieren und dabei den Fokus auf ihre DMAb-Technologie und deren revolutionäres Potenzial in der Behandlung seltener Krankheiten legen.
Die Präsentation wird die Fähigkeiten der nächsten Generation von DNA-Medizintechnologie zur Behandlung seltener Krankheiten beleuchten, im Rahmen einer Konferenz, die Branchenführer und Innovatoren zusammenbringt, um technologische und produktionstechnische Fortschritte im Bereich seltener Krankheiten zu diskutieren.
- None.
- None.
Orphan Drug Summit
Date: July 16
Time: 4:30-4:55pm ET
Presentation: DMAb Technology: The Transformational Potential of Next Gen DNA Medicine in Rare Disease
About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com.
Contacts
Media: Jennie Willson, (267) 429-8567, communications@inovio.com
Investors: Peter Vozzo - ICR Healthcare, (443) 213-0505, investor.relations@inovio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/inovio-to-present-at-upcoming-scientific-conference-302499023.html
SOURCE INOVIO Pharmaceuticals, Inc.
FAQ
When is INOVIO (INO) presenting at the Orphan Drug Summit 2025?
What will INOVIO present at the Orphan Drug Summit 2025?
Where can I watch INOVIO's Orphan Drug Summit 2025 presentation?
What is INOVIO's main business focus?
